Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy

      Abstract

      Purpose

      Hepatoblastomas often require neoadjuvant chemotherapy to facilitate partial hepatectomy, which necessitates freedom of tumor borders from the confluence of hepatic veins (COHV), portal vein bifurcation (PVB), and retrohepatic inferior vena cava (IVC). This study aimed to clarify the effect of incremental neoadjuvant cycles on the AHEP0731 protocol criteria of hepatoblastoma resectability.

      Methods

      Hepatoblastoma responses to neoadjuvant chemotherapy were analyzed among patients (n = 23) treated at two children's hospitals between 1996 and 2010. Using digital imaging data, ellipsoid and point-based models were created to measure tumor volume regression and respective distances from tumor borders nearest to the COHV, PVB, and IVC.

      Results

      Hepatoblastoma volumes regressed with incremental neoadjuvant chemotherapy cycles (p < 0.001). Although tumor borders regressed away from the COHV (p = 0.008), on average only 1.1 mm was gained. No change from tumor borders to the PVB was detected (p = 0.102). Distances from tumor borders to the IVC remained stable at one hospital (p = 0.612), but increased only 0.15 mm every 10 days of therapy at the other (p = 0.002). Neoadjuvant chemotherapy induced slightly more tumors to meet the threshold vascular margin of 1 cm (baseline to completion): COHV, 11 (47.8%) to 17 (73.9%; p = 0.058); PVB, 11 (47.8%) to 15 (65.2%; p = 0.157); and IVC, 4 (17.4%) to 10 (43.5%; p = 0.034). No differences were detected in demographic or disease-specific characteristics between patients who did or did not achieve this 1-cm margin after conclusion of chemotherapy.

      Conclusion

      Hepatoblastoma volumes regress significantly with increasing neoadjuvant chemotherapy cycles. However, tumors often remain anchored to the major hepatic vasculature, showing marginal improvement in resectability criteria.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Journal of Pediatric Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Litten J.B.
        • Tomlinson G.E.
        Liver tumors in children.
        Oncologist. 2008; 13: 812-820
        • Meyers R.L.
        • Rowland J.R.
        • Krailo M.
        • et al.
        Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group.
        Pediatr Blood Cancer. 2009; 53: 1016-1022
        • Ortega J.A.
        • Douglass E.C.
        • Feusner J.H.
        • et al.
        Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.
        J Clin Oncol. 2000; 18: 2665-2675
        • Malogolowkin M.H.
        • Katzenstein H.
        • Krailo M.D.
        • et al.
        Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
        J Clin Oncol. 2006; 24: 2879-2884
        • Czauderna P.
        • Otte J.B.
        • Aronson D.C.
        • et al.
        Guidelines for surgical treatment of hepatoblastoma in the modern era—recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).
        Eur J Cancer. 2005; 41: 1031-1036
        • Tiao G.M.
        • Bobey N.
        • Allen S.
        • et al.
        The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation.
        J Pediatr. 2005; 146: 204-211
        • Aronson D.C.
        • Schnater J.M.
        • Staalman C.R.
        • et al.
        Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study.
        J Clin Oncol. 2005; 23: 1245-1252
        • Roebuck D.J.
        • Aronson D.
        • Clapuyt P.
        • et al.
        2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group.
        Pediatr Radiol. 2007; 37 ([quiz 249–150]): 123-132
        • Lovvorn III, H.N.
        • Ayers D.
        • Zhao Z.
        • et al.
        Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics.
        J Pediatr Surg. 2010; 45 ([discussion 129]): 121-128
        • Medary I.
        • Aronson D.
        • Cheung N.K.
        • et al.
        Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery.
        Ann Surg Oncol. 1996; 3: 521-525
        • Viola P.
        • Wells III, W.
        Alignment by maximization of mutual information.
        Int J Comput Vis. 1997; 24: 137-154
        • de Boor C.
        A Practical Guide to Splines. Springer, New York1978
        • Strang G.
        Introduction to Linear Algebra.
        Wellesley-Cambridge Press, Wellesley, MA2003
        • Gore J.C.
        • Manning H.C.
        • Quarles C.C.
        • et al.
        Magnetic resonance in the era of molecular imaging of cancer.
        Magn Reson Imaging. 2011; 29: 587-600